BELGRADE, Mont. --(BUSINESS WIRE)--Apr. 28, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announced that it will release its financial results for the period ended March

BELGRADE, Mont. --(BUSINESS WIRE)--Apr. 23, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft materials and bioactive coatings for medical applications, announced today that positive results utilizing OsteoSelect ® Demineralized

Core recurring Biologics revenues up 20% from prior year First Quarter total revenue in the range of $8.7 million to $8.9 million , an increase of approximately 7% sequentially, and 2% over the same period last year. First Quarter core recurring Biologics revenue in the range of $8.55 million to

BELGRADE, Mont. --(BUSINESS WIRE)--Apr. 8, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, is pleased to announce the addition of Jimmy Bornheimer , Vice President of Finance, and

BELGRADE, Mont. --(BUSINESS WIRE)--Mar. 20, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft materials and bioactive coatings for medical applications, announces that results utilizing OsteoSponge ® bone graft for foot and ankle

BELGRADE, Mont. --(BUSINESS WIRE)--Mar. 19, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today reported financial results for the fourth quarter and full year ended December 31,

BELGRADE, Mont. --(BUSINESS WIRE)--Mar. 13, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE) is pleased to announce the launch of OsteoSTX, a new novel allograft for orthopedic procedures. Utilizing Bacterin’s proprietary demineralization technology, OsteoSTX are flexible cortical DBM

BELGRADE, Mont. --(BUSINESS WIRE)--Mar. 10, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, announced the closing of an additional $4 million financing from OrbiMed.

BELGRADE, Mont. --(BUSINESS WIRE)--Mar. 5, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone grafts and coatings for medical applications, today announced that its CEO, Dan Goldberger , will present at the Canaccord Genuity

BELGRADE, Mont. --(BUSINESS WIRE)--Feb. 25, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announced that it will release its financial results for the period ended December